Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis
Contrast-Enhanced Spectral Mammography: Potential to Improve Diagnostic Accuracy
Sponsor: Memorial Sloan Kettering Cancer Center
Terminated
Lack of accrual
Other terminated trials from Memorial Sloan Kettering Cancer Center
- Sarcoma · Phase PHASE2 · Jul 2024
- Acute Lymphoid Leukemia (ALL) · Phase PHASE2 · Mar 2024
- Gynecologic Surgery · Phase NA · Dec 2023
- Prostate Cancer · Phase PHASE2 · Jul 2023
- Diffuse Large B-Cell Lymphoma and Follicular Lymphoma · Phase PHASE1/PHASE2 · May 2023
See all terminations from Memorial Sloan Kettering Cancer Center
Listed as NCT03929822, this observational or N/A phase trial focuses on Breast Screening and remains terminated or withdrawn. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 11 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Feb 2023 — Jul 2024 [monthly]
Terminated
Status: Active Not Recruiting → Terminated
-
May 2022 — Feb 2023 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — May 2022 [monthly]
Recruiting
Phase: NA → None
▶ Show 6 earlier versions
-
May 2021 — Sep 2021 [monthly]
Recruiting NA
-
Mar 2021 — May 2021 [monthly]
Recruiting NA
-
Jan 2021 — Mar 2021 [monthly]
Recruiting NA
-
Mar 2020 — Jan 2021 [monthly]
Recruiting NA
-
Jul 2019 — Mar 2020 [monthly]
Recruiting NA
-
May 2019 — Jul 2019 [monthly]
Recruiting NA
First recorded
Apr 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .